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A Ab bs st tr ra ac ct t
B Ba ac ck kg gr ro ou un nd d: :   Cancer treatment with a variety of chemotherapeutic agents often is associated
with delayed adverse neurological consequences. Despite their clinical importance, almost
nothing is known about the basis for such effects. It is not even known whether the occurrence
of delayed adverse effects requires exposure to multiple chemotherapeutic agents, the presence
of both chemotherapeutic agents and the body’s own response to cancer, prolonged damage to
the blood-brain barrier, inflammation or other such changes. Nor are there any animal models
that could enable the study of this important problem.
R Re es su ul lt ts s: :   We found that clinically relevant concentrations of 5-fluorouracil (5-FU; a widely used
chemotherapeutic agent) were toxic for both central nervous system (CNS) progenitor cells and
non-dividing oligodendrocytes in vitro and in vivo. Short-term systemic administration of 5-FU
caused both acute CNS damage and a syndrome of progressively worsening delayed damage to
myelinated tracts of the CNS associated with altered transcriptional regulation in oligodendrocytes
and extensive myelin pathology. Functional analysis also provided the first demonstration of
delayed effects of chemotherapy on the latency of impulse conduction in the auditory system,
offering the possibility of non-invasive analysis of myelin damage associated with cancer treatment.
C Co on nc cl lu us si io on ns s: :    Our studies demonstrate that systemic treatment with a single chemo-
therapeutic agent, 5-FU, is sufficient to cause a syndrome of delayed CNS damage and provide
the first animal model of delayed damage to white-matter tracts of individuals treated with
systemic chemotherapy. Unlike that caused by local irradiation, the degeneration caused by 5-FU
treatment did not correlate with either chronic inflammation or extensive vascular damage
and appears to represent a new class of delayed degenerative damage in the CNS.
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Most treatments used to kill cancer cells also kill a diverse
range of normal cell types, leading to a broad range of
adverse side effects in multiple organ systems. In the
hematopoietic system, the tissue in which such adverse
effects have been most extensively studied, their detailed
analysis has led to the discoveries that bone marrow
transplants and cytokine therapies can improve the out-
come of many forms of cancer treatment. In contrast, there
has been no comparable level of analysis for most other
organ systems compromised by cancer treatments.
One of the tissues for which adverse side effects of cancer
treatment are clinically important is the central nervous
system (CNS). Although it has long been appreciated that
targeted irradiation of the CNS may be associated with
neurological damage, it has become increasingly clear that
systemic chemotherapy for non-CNS cancers also can have a
wide range of undesirable effects. This has been perhaps
most extensively studied in the context of breast cancer (for
examples, see [1-13]). For example, it has been reported
that 18% of all breast cancer patients receiving standard-
dose chemotherapy show cognitive defects after treatment
[9], with such problems reported in over 30% of patients
examined two years after treatment with high-dose
chemotherapy [10]; this is a greater than eightfold increase
over the frequency of such changes in control patients.
Adverse neurological sequelae include such complications
as leukoencephalopathy, seizures and cerebral infarctions,
as well as cognitive impairment [14-18]. Adverse neuro-
logical effects have been observed with almost all categories
of chemotherapeutic agents [19-22], including antimetabo-
lites (such as cytosine arabinoside (Ara-C) [23], 5-fluorouracil
(5-FU) [24,25], methotrexate [26-28], DNA cross-linking
agents (such as BCNU [29] and cisplatin [30]) and even
anti-hormonal agents [31-37]. Given the large number of
individuals treated for cancer, these adverse neurological
changes easily may affect as many people as some of the
more extensively studied neurological syndromes.
One of the most puzzling aspects of chemotherapy-induced
damage to the CNS is the occurrence of toxicity reactions
with a delayed onset. Although this has been particularly
well documented in children exposed to both chemo-
therapy and cranial irradiation [15,38-47], delayed toxicity
reactions also occur in individuals treated only with
systemic chemotherapy. For example, white matter changes
induced by high-dose chemotherapy for breast cancer, and
detected in up to 70% of treated individuals, usually arise
only several months after treatment is completed [48,49].
One widely used chemotherapeutic agent associated with
both acute and delayed CNS toxicities is 5-FU. Acute CNS
toxicities associated with systemically administered 5-FU
(most frequently in combination with other chemothera-
peutic agents) include a pancerebellar syndrome and sub-
acute encephalopathy with severe cognitive dysfunction,
such as confusion, disorientation, headache, lethargy and
seizures. With high-dose treatment, as many as 40% of
patients show severe neurological impairments that may
progress to coma [50-52]. In addition, a delayed cerebral
demyelinating syndrome reminiscent of multifocal leuko-
encephalopathy has been increasingly identified following
treatment with drug regimens that include 5-FU, with
diagnostic findings obtained by both magnetic resonance
imaging (MRI) and analysis of tissue pathology [24,53-78].
Despite the existence of multiple clinical studies describing
delayed CNS damage associated with systemic exposure to
chemotherapy, almost nothing is known about the basis for
these effects. For example, because of the multi-drug
regimens most frequently used in cancer treatment, it is not
even known whether delayed toxicities require exposure to
multiple drugs. Nor is it known whether such delayed
changes can be caused solely by exposure to chemotherapy
or if they represent a combination of the response to
chemotherapy and, for example, physiological changes
caused by the body’s reaction to the presence of a tumor. In
addition, the roles of ongoing inflammation or damage to
the vasculature in inducing such delayed CNS damage are
wholly unknown. Moreover, the absence of animal models
for the study of delayed damage makes progress in the
biological analysis of this important problem difficult.
Here, we demonstrate that delayed CNS damage in mice is
caused by short-term systemic treatment with 5-FU. Our
experiments demonstrate that CNS progenitor cells and
oligodendrocytes are vulnerable to clinically relevant
concentrations of 5-FU in vitro and  in vivo. More impor-
tantly, 5-FU exposure in vivo was followed by degenerative
changes that were markedly worse than those observed
shortly after completion of chemotherapy and that grew still
worse with time. Systemic application of 5-FU in vivo (three
injections interperitoneally (i.p.) over 5 days) was sufficient
to induce delayed degeneration of CNS white-matter tracts.
We observed this degeneration using functional, cytological
and ultrastructural analysis and by altered expression of the
transcriptional regulator Olig2, which is essential for
generation of functional oligodendrocytes. The degeneration
was not associated with either the prolonged inflammation
or the extensive vascular damage to the CNS caused by local
irradiation. This study provides the first animal model of
delayed damage to white-matter tracts of individuals treated
with systemic chemotherapy and suggests that this impor-
tant clinical problem might represent a new class of damage,
different from that induced by local CNS irradiation.
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We first examined the effects of exposure to clinically
relevant concentrations of 5-FU in vitro, as in our previous
studies on the chemotherapeutic agents cisplatin, BCNU
(carmustine) and cytarabine [79]. To estimate clinically
relevant concentrations, we used the following information:
routinely used continuous intravenous infusions of 5-FU
can result in steady-state plasma and cerebrospinal fluid
(CSF) concentrations in the range 0.3-71.0 µM, and
continuous pump infusions result in 3- to 25-fold higher
levels of exposure [80]. High-dose (bolus) injections of
5-FU can even expose brain tissue to peak concentrations in
the millimolar range [80,81], with tri-exponential elimina-
tion half-time values of 2, 12 and 124 minutes [82], and
CSF elimination half-times can be greatly extended after
localized application to brain tissue using slowly bio-
degradable polymer microspheres [83,84].
To identify potential targets of 5-FU toxicity, we first
examined the effects of clinically relevant concentrations of
5-FU on purified populations of CNS stem cells, lineage-
restricted progenitor cells and differentiated cell types. The
cells examined were: neuroepithelial stem cells (NSCs) [85];
neuron-restricted precursor (NRP) cells [86]; glial-restricted
precursor (GRP) cells [87,88]; and oligodendrocyte-type-2
astrocyte progenitor cells (O-2A/OPCs), the direct ancestors
of oligodendrocytes [89], astrocytes and oligodendrocytes
(the myelin-forming cells of the CNS). This is summarized
in Figure 1a. For comparison, we also analyzed human
umbilical vein endothelial cells (HUVECs) and cell lines
from human breast cancer (MCF-7, MB-MDA-231), ovarian
cancer (ES-2), meningioma and glioma (T98, UT-12, UT-4),
and murine lymphoma (EL-4) and murine lymphocytic
leukemia (L1210).
We found that progenitor cells and oligodendrocytes were
vulnerable to clinically relevant levels of 5-FU. Exposure to
1 µM 5-FU for 24 hours (which is at the low end of the
range of concentrations observed in the CSF of individuals
treated with 5-FU by intravenous infusion [80]) caused a
55-70% reduction in viability of dividing O-2A/OPCs and
also of non-dividing oligodendrocytes (Figure 1b). Exposure
for 24 hours to 5 µM 5-FU killed about 80% of O-2A/OPCs
and oligodendrocytes and more than 50% of GRP cells and
HUVECs. Even at concentrations as low as 0.5 µM, 5-FU
reduced the survival of O-2A/OPCs and oligodendrocytes
by approximately 45%. Exposure to 5 µM 5-FU for 5 days
killed almost all the oligodendrocytes (Figure 1c), and
exposure to 1 mM 5-FU for just 1 hour reduced the number
of viable oligodendrocytes by more than 55% (Figure 1d).
In marked contrast, these doses of 5-FU had no effect on
any of a variety of cancer cell lines, in agreement with
previous studies on the breast cancer lines examined
[90,91]. Thus, cell division was not sufficient to confer
vulnerability to 5-FU, and a lack of division by oligo-
dendrocytes was not sufficient to make them resistant.
Purified astrocytes and rapidly dividing NSCs were less
vulnerable to 5-FU than progenitor cells and oligodendro-
cytes (Figure 1b-d), although even these populations showed
some evidence of vulnerability when exposure time was
extended to 120 hours (as is often associated with continuous
intravenous infusion; Figure 1c). The relative resistance of
NSCs to 5-FU (as compared with O-2A/OPCs, GRP cells
and oligodendrocytes) demonstrates that, even in primary
cell populations, cell division is not by itself sufficient to
confer vulnerability to 5-FU.
We next investigated whether exposure to sublethal concen-
trations of 5-FU would disrupt normal progenitor cell
function by suppressing cell division, as we have seen with
BCNU, cisplatin and cytarabine [79]. Analysis of clonal
growth in these experiments was used as it provides more
detailed information on both cell division and progenitor
cell differentiation than does analysis in mass culture.
Progenitors, grown at cell densities that allow the study of
single clonally derived families of cells (as in, for example,
[92-94]), were exposed for 24 hours to 0.05 µM 5-FU (a
concentration equivalent to less than 10% of that found in
the CSF in standard-dose applications [81]), followed by
5 days of clonal growth.
Analysis of O-2A/OPC function at the clonal level indicated
that transient exposure to 0.05 µM 5-FU caused suppression
of O-2A/OPC division. Examination of the composition of
100 randomly selected clones showed that, at 5 days, the
control cultures and the cultures exposed to 0.05 µM 5-FU
contained similar numbers of oligodendrocytes (154 in
control cultures (Figure 2a), and 175 in 5-FU cultures
(Figure 2b)) but less than half as many O-2A/OPCs (336 in
control cultures versus 151 in 5-FU cultures). There was a
>85% reduction in the number of clones containing 8 or
more progenitors (these clones comprised 13% of control
cultures versus only 2% of 5-FU-treated cultures), along
with a more general shift towards clones with fewer
progenitors (Figure 2). There was also a greater than two-
fold increase in the number of clones consisting of just one
or two oligodendrocytes and no progenitors. In control
cultures, 16% of clones had such a composition, compared
with 35% in cultures transiently exposed to 0.05 µM 5-FU.
As clones were all initiated from single purified O-2A/OPCs,
these results demonstrate that transient exposure of these
progenitor cells to sublethal concentrations of 5-FU did not
prevent the subsequent generation of oligodendrocytes,
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cells (Figure 1b-d). As these cultures do not contain
macrophages (which would ingest dead cells), cell death is
easily observed by visual inspection and was found to be a
relatively rare event, affecting ≤10% of total cells. Thus, it
appears that the major cause of the lower cell numbers in 5-
FU-treated cultures was a reduction in progenitor cell
division, an interpretation consistent with the outcomes of
the in vivo analyses discussed below.
S Sy ys st te em mi ic c   t tr re ea at tm me en nt t   w wi it th h   5 5- -F FU U   c ca au us se es s   i in nc cr re ea as se es s   i in n   a ap po op pt to os si is s
a an nd d   p pr ro ol lo on ng ge ed d   r re ed du uc ct ti io on ns s   i in n   c ce el ll l   d di iv vi is si io on n   i in n   t th he e   a ad du ul lt t   C CN NS S
In vivo treatment of mice with 5-FU (40 mg kg-1, 3 injections
i.p. on days -4, -2 and 0 from the end of treatment; exposure
determined as discussed in Materials and methods) caused
significant induction of apoptosis in the multiple CNS
regions examined (Figure 3a-c). For example, at day 1 after
treatment, there was a 2.5-fold increase in apoptosis in the
subventricular zone (SVZ) and a 4-fold increase in the
dentate gyrus of the hippocampus (DG). The increased cell
death persisted in the SVZ and DG for at least 14 days, but
was at near normal values at 56 days and 6 months after
treatment (Figure 3a,c). In the corpus callosum (CC) there
was also a significant increase in apoptosis at day 1 to approxi-
mately 70% above control values (Figure 3b; p < 0.05).
Confocal microscopic analysis of immunolabeling and
terminal deoxynucleotidyltransferase-mediated dUTP nick-
end labeling (TUNEL) staining confirmed that the
vulnerability of cells in vivo was similar to that observed in
vitro (Figure 3d). In untreated animals, TUNEL+ cells (which
are apoptotic cells) were very rare, but such cells were
frequently found in the SVZ, DG and CC of animals
receiving chemotherapy. In the SVZ and DG, the majority of
TUNEL+ cells observed after 5-FU treatment were double-
cortin+ (DCX+) neuronal progenitors [95], followed by
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CNS progenitor cells are vulnerable to clinically relevant levels of 5-FU exposure. ( (a a) )   A summary of the putative relationships between the different
cell types under study (for discussion of this and alternative views on lineage relationships in the CNS, see [199,200]). Pluripotent neuroepithelial
stem cells (NSC) give rise to glial restricted precursor (GRP) cells and neuron restricted precursor (NRP) cells. GRP cells in turn give rise to
astrocytes and oligodendrocyte-type-2 astrocyte progenitor/oligodendrocyte precursor cells (O-2A/OPCs), the ancestors of oligodendrocytes. 
( (b b, ,c c) )   Primary CNS cells (b) or various cancer cell lines (c) were grown on coverslips and exposed to 5-FU for 24 h before analysis of cell viability as
described in Materials and methods. 5-FU concentrations were chosen on the basis of drug concentrations reached in humans after conventional
5-FU treatment. None of the tumor lines tested were sensitive to 5-FU treatment in this dose range, whereas O-2A/OPCs, oligodendrocytes, GRP
cells and human umbilical vein endothelial cells (HUVECs) were sensitive. ( (d d, ,e e) )   Exposure conditions designed to mimic the exposure levels
associated with long-term infusion (d) or high-dose bolus administration (e) yielded similar results, with vulnerability of O-2A/OPCs and non-dividing
oligodendrocytes to 5-FU exceeding the vulnerability of rapidly dividing cancer cells. As shown in (b,d), the vulnerability of HUVECs also exceeds the
vulnerability of cancer cells. Each experiment was carried out in quadruplicate and was repeated at least twice in independent experiments. Data
represent mean of survival ± s.e.m, normalized to control values.
5-FU 5 µM 120 h
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AstrocytesGFAP+ cells (a subset of which may be stem cells in the SVZ
[96]). The SVZ also contained a smaller number of
TUNEL+Olig2+ cells, which could be ancestors of oligo-
dendrocytes [97,98]. In the DG, there was also a very small
amount of NeuN+ mature neurons that were TUNEL+. In
the CC, approximately 70% of the TUNEL+ cells were
Olig2+, and thus would be either oligodendrocyte
progenitors or oligodendrocytes. Most of the remaining
TUNEL+ cells in the CC were GFAP+, which in this tissue
would mean they are astrocytes. The specificity of TUNEL
labeling is demonstrated by representative images of
TUNEL+ cells that were DCX+, Olig2+ or GFAP+ (Additional
data file 1) .
Analysis of cell division (as detected by incorporation of 5-
bromo-2-deoxyuridine (BrdU)) revealed that 5-FU caused
long-lasting suppression of proliferation in the SVZ and the
DG [99,100] (in which such proliferation is thought to be a
critical component of normal tissue function) as well as in
the CC (Figure 4a-c). Exposure to 5-FU caused reductions of
cell proliferation in all three regions. In contrast with the
return of levels of cell death to control levels (at least as
detected by TUNEL staining), cell division was suppressed for
long periods of time following completion of 5-FU treatment.
In the SVZ, 5-FU exposure was associated with a 40.9 ± 2.6%
decrease in numbers of BrdU+ cells on day 1, with a
transient re-population of BrdU+ cells at days 7 and 14,
followed by a subsequent decrease in animals examined at
day 56 and 6 months after completion of treatment. It was
striking that the most significant inhibition of DNA
synthesis in the SVZ was seen at 6 months post-treatment,
when there was a 67.7 ± 3.0% decrease in the number of
BrdU+ cells compared with control animals (Figure 4a). In
the DG, suppression of DNA synthesis started on day 14
after treatment, and the greatest inhibition (60.7 ± 7.8%)
was also seen at 6 months (Figure 4c). In the CC, in
contrast, cell proliferation was significantly suppressed at all
time points examined (Figure 4b).
To determine whether exposure to 5-FU preferentially
reduced DNA synthesis in any particular cell population(s)
in vivo, we combined BrdU labeling with cell-type-specific
antibodies and analyzed individual BrdU+ cells by confocal
microscopy (see Materials and methods). We analyzed the
CNS of animals sacrificed 1 day and 56 days after the
completion of 5-FU treatment in order to examine the acute
and long-term effects of treatment.
We found that neuronal precursors and oligodendrocyte
precursors were both affected in vivo. In the CC, where there
was a 42.6 ± 2.7% reduction in the number of BrdU+ cells in
tissue sections from animals sacrificed 1 day after the
completion of treatment (Figure 4b), the proportion of
BrdU+ cells that were Olig2+ was similar between controls
and treated animals (Figure 5a,b). This result also held true
at day 56, when the proportion of Olig2+ cells among the
BrdU+ population was unchanged in untreated and treated
animals, despite a continued 53.2 ± 12.4% reduction in the
total number of BrdU+ cells observed (Figure 5c,d). As
>90% of the BrdU+ cells in the CC were Olig2+, these results
indicate that the reduction in DNA synthesis observed in
this tissue predominantly affected O-2A/OPCs [97,98,101].
In contrast with effects on putative O-2A/OPCs, there was a
somewhat enhanced loss of DCX+ cells (which would have
been neuronal progenitors [95]) from among the BrdU+
population in both the SVZ and the DG (Figure 5a-d). In
the SVZ, at 1 day after treatment, there was a dispropor-
tionate and significant reduction in the percentage of DCX+
BrdU+ cells, which represented 50.2 ± 1.9% of the cells incor-
porating BrdU in control animals and only 30.7 ± 3.9% in
animals treated with three injections of 5-FU (p < 0.01). At
day 56 the proportion of BrdU+ cells that were DCX+ was
not different between controls and treated animals,
although the total number of BrdU+ cells in the SVZ of
treated animals continued to be significantly lower than
that of the control group (only 67.7 ± 4.9% compared with
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Sublethal doses of 5-FU inhibit division of O-2A/OPCs. Clonal analysis was
used to study the effects of low-dose 5-FU (0.05 µM for 24 h) on the
division and differentiation of freshly isolated progenitor cells. O-2A/OPCs
were grown at clonal density and exposed one day after plating to ( (a a) )
vehicle alone or ( (b b) ) 0.05 µM 5-FU for 24 h, doses that killed less than 5%
of O-2A/OPCs in mass culture. The number of undifferentiated
O-2A/OPCs and differentiated cells (oligodendrocytes) was determined in
each individual clone from a total number of 100 clones in each condition
by morphological examination and by immunostaining with A2B5 and anti-
GalC antibodies (to label O-2A/OPCs and oligodendrocytes, respectively).
Results are presented as three-dimensional graphs. The number of
progenitors per clone is shown on the x (horizontal) axis, the number of
oligodendrocytes on the z (orthogonal) axis and the number of clones
with any particular composition on the y (vertical) axis. In 5-FU-treated
cultures analyzed five days after initiating 5-FU exposure, there was an
increase in the representation of small clones consisting wholly of
oligodendrocytes and clones containing large numbers of
oligodendrocytes, a reduction in the representation of large clones, a
general shift of clone size towards smaller values, and a clear reduction in
the total number of progenitor cells (see text for details). Experiments
were performed in triplicate in at least two independent experiments.
























































(b)control animals at the same time point; p < 0.01). In
contrast, in the DG, a reduction in the number of DCX+
cells was also seen, both at day 1 (with DCX+ cells
comprising only 34.3 ± 4.4% of the BrdU+ population in 5-
FU-treated mice compared with 63.2 ± 3.4% in the control
mice; p < 0.01), and at day 56 (23.7 ± 3.9% in 5-FU-treated
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Systemic 5-FU treatment causes cell death in the adult CNS. Cell death was determined using the terminal deoxynucleotidyltransferase-mediated
dUTP nick-end labeling (TUNEL) assay. The number of TUNEL+ cells was analyzed in control animals (that received 0.9% NaCl i.p.) and 5-FU-treated
animals and presented as percentage normalized values of controls at each time point. For ease of comparison, data presented in the figures show
the control value (mean set at 100% of the day 1 value) and normalized values of 5-FU treatment groups at all time points. Each treatment group and
the control group consisted of n = 5 animals at each time point. Figures show apoptosis in animals that received three bolus i.p. injections of 5-FU
(40 mg kg-1 on days -4, -2 and 0 leading up to the analysis, where day 1 of analysis equals 1 day after the last treatment with 5-FU). There was
marked and prolonged increase of cell death in the 5-FU treatment group in ( (a a) ) the lateral subventricular zone (SVZ), ( (b b) ) the corpus callosum (CC)
and ( (c c) ) the dentate gyrus (DG) at 1, 7, 14 and 56 days and 6 months following treatment. Data are means ± s.e.m.; a two-way ANOVA test was
performed on the original un-normalized data set to test the statistical significance of treatment effect and time effect. Bonferroni post-tests were
performed to compare the 5-FU-treated group and the control group at each time point. The statistical significance of the Bonferroni post-tests is
labeled in the graphs where applicable: ***p < 0.001; **p < 0.01; and *p < 0.05. Two-way ANOVA test results indicate that, in the SVZ, the
treatment effect is extremely significant (p < 0.001), the time effect is very significant (p < 0.01); in the CC, the treatment effect is not quite
significant (p = 0.06), the time effect is not significant (p = 0.74); in the DG, the treatment effect is extremely significant (p < 0.001), the time effect is
significant (p < 0.05). The effect of the interaction between treatment and time is not significant for all three regions. ( (d d) ) To determine the
immediate cellular targets of 5-FU in vivo, we examined co-analysis of TUNEL labeling with antigen expression in animals sacrificed at day 1 after
completion of 5-FU treatment. The majority of TUNEL+ cells in the SVZ and DG were doublecortin (DCX)+ neuronal progenitors. Other TUNEL+
cells in these two regions included GFAP+ cells (which could be stem cells in the SVZ, or astrocytes in the DG) and Olig2+ O-2A/OPCs. There was
also a small contribution of NeuN+ mature neurons in the DG. In the CC, the majority of TUNEL+ cells were Olig2+ (which, in this white matter
tract, would be oligodendrocytes and O-2A/OPCs), with a small contribution of GFAP+ astrocytes. Almost 100% of TUNEL+ cells were accounted




























































































































































(d)mice versus 52.2 ± 2.8% in the control mice; p < 0.01). In
the CC, exposure to 5-FU was also associated with a small
increase in the proportion of GFAP+ cells among the BrdU-
incorporating populations at both day 1 and day 56,
although such cells continued to represent a minority of the
BrdU+ cells in this tissue. In addition, BrdU+ cells that were
not labeled with any of the cell-type-specific antibodies
used in these studies were more prominent in treated
animals than in controls at day 1 (but not at day 56) in the
SVZ and were found in the DG at both time points (data
not shown). The DG was the only tissue in which these
unlabeled cells made up >10% of the entire BrdU+
population. Such cells represented about 40% and 50% of
all BrdU-labeled cells in 5-FU-treated animals at days 1 and
56, respectively, compared with about 2% and 20%,
respectively, of all BrdU-labeled cells in control animals.
A An na al ly ys si is s   o of f   a au ud di it to or ry y   f fu un nc ct ti io on n   i in n   5 5- -F FU U- -t tr re ea at te ed d   a an ni im ma al ls s
s su ug gg ge es st ts s   d de el la ay ye ed d   d di is sr ru up pt ti io on n   o of f   m my ye el li in na at ti io on n
To determine whether the exposure of experimental animals
to 5-FU was associated with functional impairment, we
investigated hearing function in treated animals at various
time points after treatment. Damage to the auditory system
is a well known correlate of treatments with cisplatin
[102,103]. This damage is associated with death of cochlear
outer hair cells, increases in the auditory brainstem response
(ABR) thresholds and decreases in transient evoked oto-
acoustic emissions (TEOAE) and distortion product oto-
acoustic emissions (DPOAE), all of which are indicators of
compromised cochlear function.
We examined the DPOAE as an indicator of cochlear function
and ABRs to provide information on changes in conduction
velocity from the ear to the brain, an indicator of myelination
status. Different peaks (called P1, P2, and so on) in the ABR
response are thought to correspond to different steps in the
transmission of information, and prior analysis of ABR inter-
peak latencies shows that loss of myelin (as in, for example,
CNS myelin-deficient mouse models [104,105]) causes
increases in specific ABR inter-peak latencies (P2-P1 and P3-
P1). Such measurements have been used by several investi-
gators to study myelination-associated problems in impulse
conduction in children with iron deficiency [106-109].
Our analysis of auditory function in 5-FU-treated animals
revealed what seems to be a previously unrecognized
consequence of chemotherapy exposure: increased latencies
of impulse transmission. Consistent with the absence from
http://jbiol.com/content/7/4/12 Journal of Biology 2008, Volume 7, Article 12 Han et al. 12.7
Journal of Biology 2008, 7 7: :12
F Fi ig gu ur re e   4 4
Systemic 5-FU exposure causes prolonged suppression of proliferation in the adult CNS. Animals were treated as described in Figure 3. The number
of BrdU+ cells was analyzed in control animals and 5-FU-treated animals and presented as percentage normalized values of controls at each time
point. For ease of comparison, data presented in the figures show the control value (mean set at 100%) of day 1 and normalized values of 5-FU
treatment groups at all time points. Each group consisted of n = 5; a two-way ANOVA test was performed on the original un-normalized data set to
test the statistical significance of treatment effect and time effect. Bonferroni post-tests were performed to compare the 5-FU-treated group and the
control group at each time point. The statistical significance of the Bonferroni post-tests is labeled in the graphs where applicable: ***p < 0.001;
**p < 0.01; or *p < 0.05. Two-way ANOVA test results indicate that: ( (a a) ) in the SVZ, both the treatment effect and time effect are extremely
significant (p < 0.001), and the interaction of treatment and time is very significant (p < 0.01); ( (b b) ) in the CC, both the treatment effect and time effect
are extremely significant (p < 0.001), and the interaction of treatment and time is very significant (p < 0.01); and ( (c c) ) in the DG, the treatment effect























































































































*the literature of reported deficits in cochlear function
associated with 5-FU administration, DPOAEs in treated
animals were not significantly different from those in
untreated animals. In contrast, treated animals showed a
progressive alteration in ABRs when inter-peak latencies
were examined at days 1, 7, 14 and 56 after completion of
treatment and compared with baseline measurements of
each individual 1 day before 5-FU application.
In contrast with the lack of effect of 5-FU treatment on
DPOAEs, comparison of the changes in inter-peak latencies
P2-P1 and P3-P1 with those of a sham-treated control group
revealed that at the later time points of day 14 and day 56,
both inter-peak latency values of 5-FU-treated animals
showed marked increases (indicative of myelin damage or
loss), whereas those of sham-treated controls did not
(Figure 6). For example, at day 14, the P2-P1 and P3-P1
inter-peak latencies in 5-FU-treated animals increased by
0.179 ± 0.022 ms and 0.146 ± 0.050 ms, respectively, whereas
in control animals these latencies decreased by 0.037 ±
0.078 ms (p < 0.05 compared with 5-FU group) and 0.087 ±
0.123 ms (p  < 0.01 compared with the 5-FU group). To
place these changes in context, a 0.1 ms delay in nerve
impulse transmission is considered to be a highly signifi-
cant functional change [104,110,111]. At day 56, the P2-P1
and P3-P1 inter-peak latencies in 5-FU-treated animals
increased by 0.191 ± 0.052 ms and 0.136 ± 0.088 ms, respec-
tively, whereas in control animals the P2-P1 inter-peak
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Cell-type analyses of BrdU+ cells in control and 5-FU-treated animals at early and late time points after completion of treatment. Co-analysis of BrdU
incorporation with antigen expression was conducted as described in Materials and methods. Both control and 5-FU-treated groups were analyzed
at (a a, ,b b) day 1 and (c c, ,d d) day 56 to evaluate the immediate and long-term effects of 5-FU treatment. Results indicate that division of both DCX+
neuronal progenitors and Olig2+ oligodendrocyte precursors was reduced by systemic exposure to 5-FU. In the CC, the reduction in apparent
division of Olig2+ cells was proportionate to the overall reduction in all BrdU+ cells. In the SVZ, there was an enhanced reduction of DCX+ cells
from among the BrdU+ population at day 1 but not at day 56. In the DG, there was an enhanced reduction in the dividing DCX+ population at both
day 1 and day 56. In addition, the proportion of GFAP+ cells in the CC was increased among the BrdU+ population at both time points examined.
















































































































































(c) (d)latency showed a small increase of 0.035 ± 0.075 ms
(p < 0.05 compared with the 5-FU group), and the P3-P1
inter-peak latency decreased by 0.002 ± 0.088 ms (p < 0.01
compared with the 5-FU group). At earlier time points,
there were no increases greater than 0.1 ms in these inter-
peak latencies in either the control or the treated groups.
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The results of our ABR analysis raised the possibility that 5-
FU-treated animals show a syndrome of delayed white
matter damage. Although our analysis of cell division and
cell death following systemic treatment with 5-FU revealed
a long-lasting suppression of cell division in the CC, we
observed only an increased level of apoptosis in this tissue
at one day after the cessation of treatment. We therefore
conducted a more detailed analysis of the CC, the major
myelinated tract in the rodent CNS.
Our further investigations revealed that systemic 5-FU
exposure was sufficient to cause substantial delayed
abnormalities in oligodendrocyte biology, in regard to both
transcriptional regulation and maintenance of myelin
integrity. Following treatment of six- to eight-week-old CBA
mice with three injections of 5-FU (40 mg kg-1, every other
day over 5 days), we first observed a slight increase in Olig2+
cells in the CC at day 1 after completion of treatment.
Examination at later time points, in contrast, revealed a
substantial fall in the numbers of these cells. At day 56 after
treatment, the number of Olig2+ cells was markedly
decreased, to 32.4 ± 9.7% (p < 0.001) of control levels at this
time point (Figure 7a-c). Immunofluorescence staining with
an anti-myelin basic protein (anti-MBP) antibody revealed
that there was also markedly decreased MBP staining in
animals treated with 5-FU examined 56 days after treatment
(data not shown). When we double-labeled sections with
the anti-CC1 antibody (to identify oligodendrocytes [112]),
however, we found that the reduction in the number of
Olig2+ cells seen at day 56 was not matched by a similar fall
in the number of CC1+ oligodendrocytes. Thus, whereas
almost all CC1+ oligodendrocytes in the CC of the controls
were co-labeled with anti-Olig2 antibodies at day 56, in 5-
FU-treated animals many CC1+ oligodendrocytes showed no
detectable expression of Olig2 (Figure 7d-i).
Ultrastructural analysis of the CC of animals 56 days after
treatment supported the interpretation of our immuno-
cytochemical analyses that many oligodendrocytes were
present at this time point, but also demonstrated the presence
of abundant myelin pathology. As shown in Figure 8, midline
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Systemic 5-FU treatment caused delayed increases in auditory brainstem response (ABR) inter-peak latencies P2-P1 and P3-P1. Baseline ABR
hearing tests were performed on each animal one day before initiation of treatment with 5-FU (as for Figure 4). After treatment ended, follow-up
ABR tests were conducted on each animal at various points during a time course of 56 days. Control and treatment groups both consisted of n = 4
animals. ABR latencies were analyzed for each individual at each time point, and change of latency was calculated as Lt - L0 (Lt, latency values at day
1, day 7, day 14, or day 56 post treatment; L0, baseline latency values 1 day before treatment initiation). ( (a a) ) The change of inter-peak P2-P1 latency
values; ( (b b) ) the change of inter-peak P3-P1 latency values. At the later time points day 14 and day 56, both P2-P1 and P3-P1 inter-peak latency values
of 5-FU-treated animals show average increases of more than 0.13 ms, whereas the same inter-peak latency values of sham-treated controls show
average decreases or an increase of less than 0.04 ms. Data are mean ± s.e.m. Statistical significance of the difference between the means of control
and treated groups was p < 0.05 in (a), and p < 0.01 in (b) (confidence interval = 95%; paired, one-tailed Student’s t-test).
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Systemic 5-FU treatment causes delayed dysregulation of Olig2 expression in oligodendrocytes in the CC. Animals were treated with 5-FU as in
Figure 3 and analyzed for expression of Olig2 in the CC at various time points. There was a marked reduction in the number of such cells at 56 days
(( (a a) )   control; ( (b b) ) 5-FU) after completion of treatment, but not at 1 or 14 days after treatment. ( (c c) ) Percent-corrected number of Olig2+ cells in the
CC at day 1 and day 56 post-treatment with 5-FU, normalized to control values at each time point. Data represent averages from three animals in
each group, shown as mean ± s.e.m (* *p < 0.001, one-way ANOVA) in comparison with control values at each time point. The scale bar represents
150 µm. ( (d d- -i i) )   Representative confocal micrographs showing loss of Olig2 expression in a subset of CC1+ oligodendrocytes in the CC of a 5-FU-
treated animal at day 56 in comparison with a sham-treated animal at the same time point. The reduction in numbers of Olig2+ cells seen at day 56
after treatment was not associated with an equivalent fall in oligodendrocyte numbers, as determined by analysis of CC1+ expression. (d-f) In control
animals, there is a close equivalence between CC1 expression (d) and Olig2 expression (e); a merged image is shown in (f). Three Olig2+ CC1- cells
can be seen in (e,f) (arrowheads), which are probably O-2A/OPCs. (g-i) In contrast, in 5-FU-treated animals there is a reduction in the number of
Olig2+ cells (h), but the CC of these animals contains many CC1+ cells (g) that do not express Olig2 (i) (arrows, Olig2+ CC1+; arrowheads, Olig2+
CC1- cells). The scale bar represents 25 µm.longitudinal sections of CC displayed scattered foci of
demyelinated axons, including partial or complete loss of
myelin sheaths and increases in inter-laminar splitting of the
myelin sheaths. Analysis of transverse sections (Figure 9)
provided further evidence of myelin vacuolization and
breakdown. It was also of interest to note the axonal
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Delayed myelin and axonal degeneration in the CC caused by systemic
5-FU treatment (representative electron micrographs of longitudinal
sections of axons). Sections were taken from midline coronal sections
of the CC. ( (a a) ) A representative image from a sham-treated control
animal, showing normal myelinated axons and the normal axonal
cytoskeleton structures; ( (b b- -f f) ) representative images from a 5-FU-
treated animal, showing several pathological changes of both the myelin
and axonal structures. Asterisks, axonal abnormality; single arrows,
damaged myelin sheaths; double arrows, myelin debris; arrowheads,
engulfed myelin debris. (b) Several swollen axons with disrupted
cytoskeleton (asterisks), damaged myelin sheaths (single arrows) and
myelin debris (double arrows) can be seen. (c) Several swollen axons
(asterisks) with or without myelin can be seen, the axoplasm of which
show disruption of cytoskeleton and altered organelles. (d) Several
axons (asterisks) with absent or degenerating myelin (arrows) can be
seen; one axon shows a severely damaged axonal structure and myelin
on one side of a node of Ranvier (n) and partially disrupted myelin
sheath on the other side (arrow). (e) Several loci of myelin
degeneration can be seen (arrows); one axon seems to be transected
on one side of a node of Ranvier (n). An axon next to it shows partial
degeneration of the myelin sheath and disruption of the cytoskeleton
(asterisk). (f) Edema in what is likely to be a process of an astrocyte can
be seen, with some engulfed myelin debris (arrowhead) and the
adjacent axons are distorted; there are also swollen axons (asterisks)
with and without myelin (arrows).
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Ultrastructural evidence of myelinopathy in 5-FU-treated animals.
Electron micrographs were taken from the midline transverse sections
of the CC (cross-sections of the axons). ( (a a) ) A representative image
from a sham-treated control animal, showing normal myelinated axons;
( (b b- -f f) ) representative images from a 5-FU-treated animal, showing
multiple pathological changes of both the myelin and axonal structures.
Single asterisks indicate demyelinated axons with rarefaction (that is,
decreased density of the axoplasm staining possibly due to disruptions
in cytoskeletal structures and organelles); double asterisks indicate an
abnormal axon with partially destructed myelin sheaths; single arrows
indicate inter-laminar splitting of the myelin sheaths; and double arrows
indicate myelin debris. (b) Two axons with damaged myelin sheaths
(asterisks), myelin debris (double arrows) and a smaller axon that
seems to be detaching from its myelin sheath (single arrow) can be
seen. (c) A large demyelinated axon with rarefaction of the axoplasm
(asterisk) and two axons with collapsed centers and inter-laminar
splitting of the myelin sheaths (arrows) can be seen, indicating on-going
myelin degeneration. (d) Two large axons with completely (asterisk) or
partially (double asterisks) damaged myelin can be seen, the axoplasm
of which shows altered cytoskeleton and organelles. One axon has a
collapsed center and inter-laminar splitting (arrow). (e) Myelin debris
can be seen, possibly from a degenerating axon (double arrows) and an
axon with inter-laminar splitting (arrow). (f) A demyelinated axon with
rarefaction of the axoplasm and possible axonal swelling (asterisk) and
two neighboring axons with inter-laminar splitting (arrows) can be seen.pathology observed in these ultrastructural studies. Transverse
sections revealed degenerating axons with multi-laminated
structures and collapsed centers, swelling of axons and altered
axonal cytoskeleton and organelles. In the transverse sections,
pathological changes in axons were also readily apparent and
included axonal swelling and focal degeneration of the
axoplasmic cytoskeleton and microtubules.
Despite the presence of BrdU+ Olig2+ cells in day 56 CC,
raising the possibility of repair of the myelinopathy found
at this time point, examination of animals six months after
5-FU treatment revealed eventual loss of almost all cells and
myelin in this tissue. Hematoxylin and eosin staining
revealed markedly decreased cellularity in the CC in treated
animals at the 6 month time point, along with markedly
decreased levels of MBP in the CC and in the white-matter
tracts of the striatum of treated animals (Figure 10). In
agreement with the majority of the cell bodies in the mature
CC belonging to oligodendrocytes or glial progenitor cells,
the decrease in the number of CC1+ cells at 6 months
matched the decrease of Olig2 labeling (data not shown),
confirming loss of oligodendrocytes at this time point.
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The occurrence of delayed damage to the CNS following
irradiation has been a subject of interest for many years, and
both vascular damage and delayed inflammatory reactions
have been implicated as being important in the adverse
effects of this treatment on the CNS [113-116]. To begin to
determine whether similar mechanisms might be relevant
to analysis of the delayed effects of 5-FU administration, we
examined microglial activation and endothelial cell apop-
tosis in 5-FU-treated animals.
Unlike the consistent observations of microglial activation
in the irradiated CNS [116], such evidence of inflammation
following treatment with 5-FU was observed in only one of
ten treated animals and only at day 1 after the cessation of
treatment. Inflammatory reactions were examined in sections
labeled with antibody directed against the mouse antigen
F4/80, a 160 kDa glycoprotein expressed by activated murine
microglia and macrophages [117]. We found that F4/80
staining was markedly increased at day 1 in one of the ten
mice treated with 5-FU (Figure 11a,b). In this animal, there
was diffuse microglial activation throughout the brain,
including the primary motor cortex, CC, periventricular
striatum and hippocampus. The activation of microglia
seemed to be an acute inflammatory reaction, however,
since it was not found in any treated animals at later time
points. Thus, inflammation was not a frequent response to
treatment with 5-FU, and no prolonged inflammatory
reactions similar to those seen following irradiation were
observed in our experiments.
Damage to the vasculature following irradiation has also
been suggested as a possible contributor to delayed CNS
damage but, as for inflammation, it seems unlikely that such
damage contributed to the delayed effects of 5-FU
administration. Analysis of TUNEL labeling in 5-FU-treated
animals revealed a subset of animals (four out of ten total
treated animals from two independent experiments) that
showed markedly increased diffuse TUNEL+ nuclei; the
distribution, morphology and size of these nuclei resembled
those of the microvasculature endothelial cells of the CNS
(Figure 11c-e). Double-labeling to visualize expression of
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5-FU treatment causes reduced cellularity and loss of myelin basic
protein (MBP) at 6 months after treatment. Representative images of
hematoxylin and eosin staining from the periventricular region of 
( (a a, ,c c) ) a control animal and ( (b b, ,d d) ) a 5-FU-treated animal. (c) Partial
enlargement of the CC shown in (a); (d) partial enlargement of the CC
shown in (b). (a) Normal cellular density is seen in the CC of the
control; (b) in the CC from a 5-FU-treated animal, the cellular density
in the CC has decreased markedly. ( (e e, ,f f) ) The expression of MBP seen in
control animals (e) (the fiber-like green fluorescence staining in the CC
and white-matter tracts in the peri-ventricular striatum) is greatly
reduced in treated animals (f). The bright green punctuated fluorescent
staining is BrdU+ cells, which are present in control animals but greatly
depleted in treated animals. All sections were processed at the same
time and all images were taken under equal exposure times. The scale
bar represents 100 µm.the vascular endothelial cell marker PECAM/CD31 [118]
confirmed that these apoptotic cells were vascular
endothelial cells (Figure 11c-e). However, these indications
of vascular damage were seen only in a subset of animals
examined 1 day after the cessation of treatment and were
not observed in animals examined at any later time points.
D Di is sc cu us ss si io on n
Our studies demonstrate that systemic treatment with 5-FU
is associated with both acute and delayed toxicity reactions,
outcomes that are of particular concern because of the use
of this agent in the treatment of many cancers. As in our
recent studies on cisplatin, cytarabine and carmustine [79],
in vitro analysis of vulnerability to 5-FU revealed that
lineage-restricted progenitor cells of the CNS and non-
dividing oligodendrocytes were vulnerable to the effects of
5-FU at or below clinically relevant exposure levels. Thus,
toxicity of 5-FU was not limited to dividing cells. Toxicity of
5-FU was not limited to induction of cell death and was also
associated with suppression of O-2A/OPC division, even
when applied transiently at exposure levels that represent
small fractions of the CNS concentrations achieved during
cancer treatment. Although previous in vitro studies on
neurons and oligodendrocytes also observed vulnerability
of these cells [119,120], the effective concentrations used in
our present study are considerably lower than those used in
previous studies. Our in vitro analyses also predicted the
acute in vivo effects of 5-FU with considerable accuracy, just
as was the case with our previous studies on cisplatin,
BCNU and cytarabine [79]. 5-FU exposure transiently
increased apoptosis and suppressed proliferation for
extended periods of time in the SVZ, DG and CC. Cell-type-
specific analyses confirmed that the main populations
affected  in vivo were also progenitor cells and oligo-
dendrocytes. Suppression of progenitor cell proliferation
was also seen in vitro in analyses of division and
differentiation in clonal families of cells.
This study is the first to demonstrate that delayed
degenerative damage can be caused by systemic application
of a single chemotherapeutic agent (5-FU) and does not
require the concurrent presence of cancer to manifest, as
well as the first to provide an animal model of delayed
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5-FU induces transient inflammation and apoptosis of microvasculature endothelial cells in a subset of treated animals. Representative photographs
showing the inflammatory response on day 1 after treatment with ( (a a) ) vehicle or ( (b b) )   5-FU treatment as indicated by immunostaining for the activated
microglia/macrophage marker F4/80. The basal level of F4/80 staining was very low in the controls but increased after treatment. These sections are
from the CC (the region between the two dotted lines), with similar evidence of inflammation seen in the DG and cortex of this same mouse. The
scale bar represents 50 µm. ( (c c- -e e) )   TUNEL/PECAM (CD31) double immunostaining was performed in 5-FU-treated animals, with representative
images taken from the DG showing double-labeling of the vascular endothelial cell marker PECAM (CD31) with TUNEL+ nuclei. In the subset of
animals in which evidence of endothelial cell death was observed, similar TUNEL+ profiles were also found in the cortex and CC.damage to white matter associated with the systemic
administration of chemotherapy. These results are of
particular interest in the context of many clinical reports
that have identified neurotoxicity as a complication of
treatment regimens in which 5-FU is a component. Although
most reports of 5-FU-associated neurotoxicity indicate a
relatively acute onset, a delayed demyelinating cerebral
complication reminiscent of multifocal leukoencephalo-
pathy has also been increasingly reported in patients treated
with chemotherapy regimens that include 5-FU [24,53-78].
Although 5-FU is used most extensively in the treatment of
colorectal cancers, it is also an important component of
adjuvant therapies for the treatment of a variety of other
cancers, including breast [121-128], gastric [129-136], pan-
creatic [137-142] and lung [129,143,144], and is thus given
to large numbers of patients. Neurological symptoms may
occur in some patients several months after adjuvant
therapy with 5-FU and include declines in mental status,
ataxia and the appearance of prominent multifocal enhan-
cing white matter lesions detectable by MRI. In addition,
both acute and delayed neurological side effects have been
observed for many other chemotherapeutic agents
[9,14,23,26,27,29-31,33,145-154], and it will be of interest
to determine whether the pattern of degenerative changes
observed with 5-FU exposure is representative of delayed
changes associated with other chemotherapeutic agents.
We also have provided several novel findings regarding the
problem of delayed white matter damage caused by 5-FU
exposure. Our findings of aberrant regulation of Olig2
expression, with the presence of many Olig2-negative oligo-
dendrocytes at 56 days after treatment, provide the first
indication that chemotherapy alters the normal expression
of important transcriptional regulators in oligodendrocytes.
Our ultrastructural studies demonstrate extensive myelin
pathology at this time point, along with indications of
neuronal pathology. It is not yet known whether damage to
myelin precedes damage to neurons (as is thought to occur
in multiple sclerosis (see, for example [155-162]), or whether
neuronal damage occurs concurrent with or preceding myelin
pathology. The vulnerability of oligodendrocytes to 5-FU in
vitro and the increased apoptosis in these cells following 5-
FU exposure in vivo, however, suggests strongly that
oligodendrocytes are a direct target of this anti-metabolite.
Although this is a somewhat surprising result (in that 5-FU
has been thought to target dividing cells specifically, while
oligodendrocytes do not divide in the conditions used in
our experiments), previous studies have shown that
experimental derivatives of 5-FU, and its metabolites, also
cause myelin damage in vitro and in vivo [163,164]. Whether
5-FU derivatives such as capecitabine (an orally active form
of 5-FU) cause similar damage is not yet known, but the
presence of the activating enzyme for this drug (thymidine
phosphorylase) in white-matter tracts [165] makes this a
matter of concern.
Although the continuing presence of at least some BrdU+
cells in the CC at 56 days offered the possibility that the
damage to myelin occurring at this time point might be
reversible, analysis at 6 months demonstrated a striking loss
of cells and of MBP. Thus, it appears that even a short-term
exposure to 5-FU can cause long-term and apparently
irreversible damage to white-matter tracts.
Analysis of alterations in myelination caused by chemo-
therapy would benefit enormously from the ability to
conduct functional analysis in a non-invasive manner, and
our analysis of alterations in inter-peak latencies in ABRs
provides a tool of particular potential interest in this regard,
as well as revealing a novel form of chemotherapy-induced
neurological damage. Despite extensive investigations of
ototoxicity induced by exposure to cisplatin (for reviews, see
[166-171]), such studies appear to have been focused
exclusively on the effects of chemotherapy on hair cells and
cochlear function and have not used ABR analysis of inter-
peak latencies to analyze changes that may be related to
white matter damage. Thus, our ABR analyses seem to
provide the first demonstration of adverse effects of
chemotherapy on a functional outcome related to CNS
myelination. ABR inter-peak latency analysis has been used,
however, to study myelination-related maturation and
function of the auditory pathway in normal infants in
conditions in which myelination is compromised (for
example, iron deficiency, fetal cocaine syndrome) and in
experimental animals [105,106,108,172-175]. Thus, this
approach provides a non-invasive functional analysis of a
myelination-related outcome measure that can be used in
both experimental animals and human populations.
The progressive alterations in ABR inter-peak latencies
observed in our studies also highlight the fact that at least
some of the delayed damage associated with 5-FU adminis-
tration is greater than the damage observed acutely. The
ability to study progressive deterioration in the same
animals over prolonged periods will make this approach of
particular value in further investigations of these changes.
Moreover, because of the ease of conducting such studies in
humans, such analysis may provide a simple, non-invasive
approach to the analysis of adverse effects on white matter
complementary to the imaging-based detection of leuko-
encephalopathy.
The underlying causes of delayed damage induced by
chemotherapy will be the subject of continued investigation,
but the observations that vascular damage and inflammatory
reactions were rare and were observed only at short intervals
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these are causally important. This is in striking contrast to
the effects of irradiation, where inflammation is thought to
be essential in delayed suppression of hippocampal
neurogenesis [115,116]. It is possible that the appearance of
delayed damage following 5-FU treatment reflects the
combined effects of delayed oligodendrocyte death and a
loss of the progenitor cell populations required for
replacement. Recent findings that aging is associated with a
loss of expression of important transcriptional regulators,
including Olig2, in oligodendrocytes [176] and may be
associated with degenerative white matter changes [177-
185] also raises the possibility, however, that the effect of
5-FU results from an acceleration of the normal aging
processes.
Our findings also raise the question of whether multiple
pathological changes contribute to the effects of chemo-
therapy on cognition. The ability of irradiation to the CNS
to suppress the generation of new neurons in the hippo-
campus has been suggested to be relevant to the
understanding of cognitive impairment associated with this
particular form of cancer treatment [115]. Although reduced
numbers of dividing hippocampal neuronal progenitors are
also seen in association with exposure to 5-FU, BCNU or
cytarabine [79], the additional damage to white-matter
tracts caused by chemotherapy would be expected to impair
normal neuronal impulse conduction (in accordance with
the changes in ABR latency seen here) and thus might also
contribute to alterations in cognition. It is particularly
interesting in this regard that recent studies on breast cancer
patients treated with adjuvant chemotherapy have revealed
that, relative to controls, patients had slower speeded
processing and altered fractional anisotropy (a measure of
white matter integrity) in the corpus callosum.  It has been
suggested that these white matter changes are related to the
cognitive deficits that may be associated with treatment
with systemic chemotherapy [186].
As adverse effects on several normal tissues have been
observed for almost all classes of chemotherapeutic agents
[19-22,187] (including alkylating agents [29,30], anti-
metabolites [23-26,57], methotrexate [27] and even anti-
hormonal agents [31-37]) and such treatments will clearly
remain the standard of care for cancer patients for many
years to come, the need to understand such damage better is
great. Indeed, some of the most important advances in the
treatment of cancer have emerged from the study of such
damage, the necessary first step in its prevention. Moreover,
evaluation of potential new therapeutics that does not
include adequate analysis of these potential toxicities may
lead to the approval of treatments that are no better than
existing treatments in avoiding serious damage to normal
tissue. The clinical study of such side effects does not
provide the experimental foundations required for the
analysis of such problems. Indeed, treatment for neuro-
logical complications of 5-FU treatment has largely been
ineffective so far, with some patients responding to
immediate discontinuance of chemotherapy and steroid
treatment [57,60], but with others continuing to deteriorate
and, in some severe cases, progressing to death [188]. In
contrast, recent studies on the toxicities in vitro and in vivo of
several chemotherapeutic agents [79,189], and our discovery
of an animal model for delayed damage to the CNS caused
by chemotherapy, provide experimental foundations that
should prove of great value in the discovery and evaluation
of therapies that either allow selective killing of cancer cells
or offer selective protection to the normal cells of the body.
M Ma at te er ri ia al ls s   a an nd d   m me et th ho od ds s
Most materials and methods are as described in [79] and are
presented here in brief.
P Pr re ep pa ar ra at ti io on n   o of f   p pr ri im ma ar ry y   c ce el ll l   c cu ul lt tu ur re es s
In vitro studies were performed on purified cultures of
primary CNS cells isolated from the developing rat CNS.
Purified populations of neuroepithelial stem cells, neuron
restricted precursor cells, glial restricted precursor cells,
O-2A/OPCs, oligodendrocytes and astrocytes were all
prepared and grown as described previously [79]. HUVECs
(Cambrex) were cultured in endothelial growth medium
(EGM-2) and used within two passages after thawing.
Cancer cell lines used were established breast cancer cell
lines (MCF-7 and MDA-MB-231), ovarian cancer (ES-2) cells,
L1210 lymphocytic leukemia and EL-4 lymphoma cells, a
meningioma cell line and two cell lines isolated from
patients with glioblastoma multiforme (UT-4 and T98 cell
lines); these were grown as previously described [79].
I In n   v vi it tr ro o t to ox xi ic ci it ty y   a an nd d   v vi ia ab bi il li it ty y   a as ss sa ay y
In vitro toxicity studies involved microscopic analysis of
staining with the 3,(4,5-dimethylthiazol-2-yl) 2,5-diphenyl-
tetrazoliumbromide (MTT) assay in combination with 4’,6-
diamidino-2-phenylindole (DAPI) and staining with cell-
type-specific antibodies, as previously described [79]. Each
experiment was carried out in quadruplicate and was
repeated at least twice in independent experiments. Data
points represent means from single experiments and error
bars shown in figures represent ± standard error of the mean
(s.e.m).
C Cl lo on na al l   a an na al ly ys si is s
Clonal analysis of O-2A/OPC division and differentiation
was carried out as described previously [92-94]. One day
after plating, cells were exposed for 24 h to low-dose 5-FU
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killing of O-2A/OPCs in mass culture. The number of
undifferentiated progenitors and differentiated oligo-
dendrocytes was determined in each individual clone from
a total of 100 clones in each condition by morphological
examination and by immunostaining to confirm cell-type
identification. Experiments were performed in triplicate in
at least two independent experiments.
C Ch he em mo ot th he er ra ap py y   a ap pp pl li ic ca at ti io on n   i in n   v vi iv vo o
For in vivo experiments, 6-8-week-old CBA mice were treated
with chemotherapy under approved protocols. 5-FU
(Sigma) was administered by i.p. injections. Animals
received 5-FU as three consecutive injections every other
day (40 mg kg-1 body weight). Control animals received
equal amounts of 0.9% NaCl i.p.. Animals were sacrificed
on days 1, 7, 14 and 56 and 6 months after completion of
treatment with 5-FU (where day 0 is the time of the last
injection of the agent). For all in vivo experiments, animals
were perfused transcardially with 4% paraformaldehyde in
phosphate buffer (pH 7.4), under deep anesthesia using
Avertin (tribromoethanol; Sigma; 250 mg kg-1, 1.2%
solution).
We chose the in vivo dosage on the basis of conversion from
human treatment dosage to an equivalent mouse dosage
and previous animal studies of 5-FU effects in mice. As is
standard practice, we used a conversion factor of 3
[190-194] to calculate the equivalent mouse dose range
(20-1,167 mg kg-1) from the clinical human treatment dose
range (60-3,500 mg m-2). On the basis of animal studies in
mice (for example, [195-197]), in which doses of 5-FU used
ranged from 40-200 mg kg-1, we first used 60 mg kg-1 every
other day for three doses as the initial trial treatment. As this
treatment caused death in half of treated CBA mice one
week after completion of treatment, we lowered the dosage
to 40 mg kg-1, which was tolerated well by the animals (it
caused less than a 10% increase in death over a six-month
period compared with sham-treated controls). The
differences in tolerance to 5-FU treatment between our
study and others may result from the different mouse
strains used. In clinical practice, patients are often given the
highest tolerated dosage of chemotherapy to achieve
maximum fractional kill of the malignant cells. Considering
this situation, we determined the appropriate in vivo dosage
to be 40 mg kg-1.
I Im mm mu un no of fl lu uo or re es sc ce en nc ce e, ,   T TU UN NE EL L   s st ta ai in ni in ng g   a an nd d   a an na al ly ys si is s   o of f   B Br rd dU U
i in nc co or rp po or ra at ti io on n   i in n   v vi iv vo o
All  in vivo analysis was carried out as described in [79].
Using free-floating sections (40 µm), detection of nuclear
profiles with DNA fragmentation, a hallmark of apoptosis,
was performed using a TUNEL assay combined with DAPI
counterstaining to visualize nuclear profiles. To combine
TUNEL staining with immunofluorescence staining for
different cell lineage markers, TUNEL staining was performed
first, followed by labeling with one of the following primary
antibodies for 24-48 h: mouse anti-NeuN (1:500,
Chemicon), goat anti-DCX (doublecortin; 1:500, Santa
Cruz), rat anti-S-100β (1:2,500, Swant), mouse anti-MBP
(1:1,000, Chemicon), mouse anti-GFAP (1:2,500, DAKO),
rabbit anti-Olig2 (1:1,000, a gift of David Rowitch), mouse
anti-CC1 (1:300, Calbiochem; which was used under
conditions [101] in which specificity for oligodendrocytes is
preserved and no double-labeling with GFAP+ astrocytes
was observed), rat anti-CD31/PECAM (1:500, Chemicon)
and rat anti-F4/80 (Abcam). All secondary antibodies,
generated in donkey (anti-rat, anti-rabbit, anti-goat and
anti-mouse), were coupled to TritC, FitC or Cy5 (Jackson
ImmunoResearch) for in vivo staining and were used
according to the species of primary antibody. Fluorescent
signals were detected using a confocal laser scanning
microscope Leica TCS SP2 and a 40× oil immersion lens,
with pinhole settings corresponding to an optical thickness
of less than 2 µm used to avoid false positive signals from
adjacent cells.
To label the proportion of dividing cells engaged in DNA
synthesis in vivo, mice received a single injection of BrdU
(50 mg kg-1 body weight, dissolved in 0.9% NaCl) given i.p.
4 h before perfusion. Anti-BrdU antibody was used to
identify BrdU+ cells by standard techniques (as in [79]). A
minimum of 50 BrdU+ cells was counted for each labeling
condition in each animal (n = 3 animals in each group
examined), with the sole exception of the DG of the
animals examined 56 days after cytarabine treatment, for
which an identical number of sections were examined as in
controls, but the frequency of labeled cells was not
sufficient to reveal 50 cells in these sections. Quantification
of BrdU+ cells was accomplished with unbiased counting
methods. BrdU immunoreactive nuclei were counted in one
focal plane to avoid over-sampling. Brain structures were
sampled either by selecting predetermined areas on each
section (lateral SVZ) or by analyzing the entire structure on
each section (CC and DG). Differences were considered
significant when p < 0.01.
SVZ:  BrdU+ cells were counted in every sixth section (40
µm) from a coronal series between interaural anterior-
posterior (AP) +5.2 mm and AP +3.9 mm (the anterior
commissure crossing). BrdU+ cells were counted along the
lateral ventricular wall up to 200 µm distance from the
lateral ventricle wall.
CC: BrdU+ cells were counted in every sixth section (40 µm)
from a coronal series between interaural AP +5.2 mm and
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medial part of the CC and analyzed as for the SVZ.
DG:  BrdU+ cells were counted in every sixth section (40
µm) from a coronal series between interaural AP +2.5 mm
and AP +1.1 mm. BrdU+ cells were counted in the area of
the dentate gyrus, including the hilus, subgranular zone
and the granule cell layer and analyzed as for the SVZ.
Quantitative data in all figures are presented as mean
percentage normalized to control animals. Error bars
represent ± s.e.m.
To analyze BrdU incorporation in specific cell types, anti-
BrdU immunostaining was combined with immuno-
labeling to identify DCX+ neuronal precursor cells [95],
Olig2+ oligodendrocyte precursor cells (defined as cells
that were BrdU+ and Olig2+, in order to discriminate these
cells from Olig2+ non-dividing oligodendrocytes
[97,98,101]) and GFAP+ cells; the latter would have been
astrocytes in the CC or DG or, in the SVZ, may also have
been stem cells [96]. Labeling and confocal analysis was
carried out as for the combination of immunolabeling
with TUNEL staining.
A Au ud di it to or ry y   b br ra ai in n   s st te em m   r re es sp po on ns se es s
Baseline ABRs were measured in each animal one day
before initiation of treatment. After treatment ended,
follow-up ABR tests were conducted on each animal at
various points during a time course of 56 days. For the
measurement, mice were anesthetized with xylazine
(20 mg kg-1 i.p.) and ketamine (100 mg kg-1 i.p.) [198].
Needle electrodes were inserted at the vertex and pinna of
the ear, with a ground near the tail. ABR potentials were
evoked with click stimuli at 80 dB SPL. The response was
amplified (10,000×) and 1,024 responses were averaged
with an analog-digital board in a LabVIEW-driven data-
acquisition system. For comparison of change of latencies,
the wave peaks P1, P2 and P3 were identified by visual
inspection at recorded wave forms, and the inter-peak
latencies of wave P2-P1 and P3-P1 computed. The change
of inter-peak latencies was calculated as Lt - L0 (where Lt is
the inter-peak latency values at day 1, day 7, day 14, or day
56 post-treatment; and L0 is the baseline inter-peak latency
values one day before treatment initiation).
I Im ma ag ge es s   a an nd d   d da at ta a   p pr ro oc ce es ss si in ng g   a an nd d   s st ta at ti is st ti ic cs s
Digital images were captured using a Nikon Eclipse E400
upright microscope with a spot camera (Diagnostic
Instruments) and the spot advanced software for Macintosh
(Diagnostic Instruments), or using the confocal laser
scanning microscope (Leica TCS SP2). Paired or unpaired
Student  t-tests were used for statistical analyses where
applicable.
E El le ec ct tr ro on n   m mi ic cr ro os sc co op py y
The animals were anesthetized and injected with heparin
and perfused with a 0.1 M phosphate buffered 4.0% para-
formaldehyde/2.5% glutaraldehyde fixative. The brain was
removed and allowed to fix overnight at 4°C and the CC
was then sectioned sagitally and coronally at approximately
1.0 mm. The sections were rinsed in 0.1 M sodium
phosphate buffer, post-fixed in buffered 1.0% osmium
tetroxide, dehydrated in a graded series of ethanol to 100%,
transitioned to propylene oxide and infiltrated with
EPON/Araldite epoxy resin overnight. They were embedded
into mold capsules (BEEM) and polymerized for 2 days at
70°C. Sections of 1 µm were cut onto glass slides and
stained with toluidine blue to determine areas to be thin
sectioned at 70 nm onto grids. The grids were stained
sequentially with uranyl acetate and lead citrate. A Hitachi
7100 transmission electron microscope was used to
examine and digitally capture images using a MegaView III
digital camera (Soft Imaging).
A Ad dd di it ti io on na al l   d da at ta a   f fi il le es s
An additional data file is available with this article online.
Additional data file 1 shows a representative confocal
micrograph of TUNEL+ cells co-labeled with cell-type-
specific markers. (A-A”) show a TUNEL+ DCX+ cell in the
sub-ventricular zone; (B-B”) show a TUNEL+Olig2+ cell in
the CC; (C-C”) show a TUNEL+ GFAP+ cell in the CC. The
scale bars represent 10 µm.
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